文献速递心境障碍会诊联络精神医学

抑郁症患者全因及特定原因死亡风险的系统综述与荟萃分析

All-cause and cause-specific mortality in people with depression: a large-scale systematic review and meta-analysis of relative risk and aggravating or attenuating factors, including antidepressant treatment.
PubMed 文献 · World Psychiatry · 2025-01-01

这项系统综述与荟萃分析纳入268项队列研究、10,842,094名抑郁症患者和2,837,933,536名对照,发现抑郁症患者全因死亡风险翻倍(RR=2.10),自杀风险尤高(RR=9.89),自然原因死亡风险亦升高(RR=1.63);抗抑郁药使用与较低全因死亡风险相关(RR=0.79),ECT使用与降低全因、自然原因及自杀死亡风险相关。

要点

  • 抑郁症患者全因死亡风险为对照的2.10倍,自杀风险为9.89倍。
  • 伴精神病性症状或治疗抵抗的抑郁症患者死亡风险进一步升高。
  • 抗抑郁药使用与较低全因死亡风险相关(RR=0.79)。

核心结论

  • 抑郁症患者全因死亡风险翻倍,自杀风险尤其突出。
  • 伴精神病性症状或治疗抵抗的抑郁症患者死亡风险进一步增加。
  • 抗抑郁药和ECT使用与降低死亡风险相关。

研究设计与样本

  • 系统综述与荟萃分析,纳入268项队列研究,检索EMBASE、Medline和PsycINFO至2025年1月26日。
  • 纳入10,842,094名抑郁症患者和2,837,933,536名对照,采用随机效应模型合并死亡率估计。

主要发现

  • 抑郁症患者全因死亡风险为无抑郁/一般人群对照的2.10倍(RR=2.10,95%CI:1.87-2.35,I2=99.9%)。
  • 自杀死亡风险为对照的9.89倍(RR=9.89,95%CI:7.59-12.88,I2=99.6%),自然原因死亡风险为1.63倍(RR=1.63,95%CI:1.51-1.75,I2=99.6%)。
  • 匹配共病后抑郁症相关死亡风险仍显著升高(RR=1.29,95%CI:1.21-1.37,I2=99.9%)。
  • 伴精神病性症状 vs 不伴者死亡风险RR=1.61(95%CI:1.45-1.78,I2=6.3%),治疗抵抗 vs 非治疗抵抗者RR=1.27(95%CI:1.16-1.39,I2=85.3%)。
  • 抗抑郁药使用 vs 未使用全因死亡风险RR=0.79(95%CI:0.68-0.93,I2=99.2%)。

关键数值与推荐

  • ECT使用 vs 未使用与降低全因死亡风险相关(RR=0.73,95%CI:0.66-0.82,I2=0%)。
  • ECT使用 vs 未使用与降低自然原因死亡风险相关(RR=0.76,95%CI:0.59-0.97,I2=12.0%)。
  • ECT使用 vs 未使用与降低自杀死亡风险相关(RR=0.67,95%CI:0.53-0.85,I2=32.3%)。

临床怎么用

  • 临床应关注抑郁症患者的全因及自杀死亡风险,尤其伴精神病性症状或治疗抵抗者。
  • 优化抗抑郁药治疗并考虑ECT可能有助于降低死亡风险。
  • 需采取多管齐下的干预措施,包括改善躯体健康和缓解自杀风险。

局限性

  • 纳入研究间异质性高(多数I2>99%)。
  • 抗抑郁药和ECT相关结果为观察性关联,可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Depression has been reported to be associated with premature mortality. However, no meta-analysis has comprehensively examined all-cause and cause-specific mortality risk in people with this condition, focusing also on possible aggravating and attenuating factors, including antidepressant treatment. We conducted a systematic review and meta-analysis of cohort studies to synthesize mortality risk estimates associated with depression (major depressive disorder and dysthymia) due to any and specific causes, and when depression is accompanied by comorbid conditions. Effects of antidepressant medication and electroconvulsive therapy (ECT), and other potential moderators of mortality risk, were evaluated. We searched EMBASE, Medline and PsycINFO databases up to January 26, 2025, pooling mortality estimates using random-effect models. Publication bias, subgroup and meta-regression analyses, and quality assessment (Newcastle-Ottawa Scale) were performed. Across 268 studies, 10,842,094 individuals with depression and 2,837,933,536 control subjects were included. All-cause mortality was doubled in people with depression versus no depression/general population controls (relative risk, RR=2.10, 95% CI: 1.87-2.35, I2=99.9%), being especially high for suicide (RR=9.89, 95% CI: 7.59-12.88, I2=99.6%), but also elevated for natural causes (RR=1.63, 95% CI: 1.51-1.75, I2=99.6%). Among individuals with versus without depression matched for comorbid conditions, the depression-associated mortality risk was also significantly elevated (RR=1.29, 95% CI: 1.21-1.37, I2=99.9%). Depression with versus without psychotic symptoms (RR=1.61, 95% CI: 1.45-1.78, I2=6.3%), and treatment-resistant versus non-treatment-resistant depression (RR=1.27, 95% CI: 1.16-1.39, I2=85.3%), conferred an incremental mortality risk. Antidepressant use (versus no antidepressant use) was associated with significantly lower all-cause mortality in people with depression (RR=0.79, 95% CI: 0.68-0.93, I2=99.2%). ECT use (versus no ECT use) was associated with reduced all-cause mortality (RR=0.73, 95% CI: 0.66-0.82, I2=0%), natural-cause mortality (RR=0.76, 95% CI: 0.59-0.97, I2=12.0%), and suicide (RR=0.67, 95% CI: 0.53-0.85, I2=32.3%). Our results affirm heightened mortality risk in depression, identify clinically relevant patient subgroups with increased mortality risk, and highlight mortality-reducing effects of antidepressant treatment and ECT. Multipronged intervention approaches targeting physical health improvement and suicide risk alleviation, optimizing antidepressant treatment, and pursuing early identification and effective interventions for psychotic and treatment-resistant depression, could help reduce this mortality gap, which is still growing.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chan JKN, Solmi M, Lo HKY, et al. All-cause and cause-specific mortality in people with depression: a large-scale systematic review and meta-analysis of relative risk and aggravating or attenuating factors, including antidepressant treatment. World Psychiatry. 2025. PMID: 40948054. doi:10.1002/wps.21354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。